Searchable abstracts of presentations at key conferences in endocrinology

ea0078oc4.9 | Oral Communications 4 | BSPED2021

The use of Liraglutide in the treatment of childhood obesity

Apperley Louise , Erlandson-Parry Karen , Gait Lucy , Laing Peter , Senniappan Senthil

Introduction: Childhood obesity remains a major health concern and there are a number of serious complications associated with it. These include type 2 diabetes mellitus (T2DM), obstructive sleep apnoea (OSA), idiopathic intracranial hypertension (IIH) and non-alcoholic fatty liver disease (NAFLD). Glucagon-like peptide 1 (GLP-1) therapy has shown promising results for weight loss in adults and has recently been approved for the use in the treatment of childhood obesity for ad...

ea0066p71 | Learning from Mistakes and Miscellaneous | BSPED2019

Intracranial hypertension secondary to severe obesity: case series

Apperley Louise , Erlandson-Parry Karen , Laing Peter , Das Urmi , Senniappan Senthil

Introduction: The prevalence of childhood obesity is continuing to increase, especially in more deprived areas. It is estimated that 28% of children are overweight or obese in England. Evidence has shown that obesity is associated with increased intracranial pressure (ICP) in adult and paediatric populations. We report three patients who presented with intracranial hypertension due to severe obesity.Case 1: A fifteen-year-old girl presented with severe h...

ea0095oc10.1 | Oral Communications 10 | BSPED2023

The real-world experience of long acting growth hormone in children with growth hormone deficiency

Ramya Gokul Pon , Jarvis Charlotte , Laing Peter , Das Urmi , Ramakrishnan Renuka , Dharmaraj Poonam , Blair Jo , Didi Mohammed , Senniappan Senthil

Introduction: Long-acting growth hormone (LaGH) therapy has emerged as a newer treatment option for children, with the potential to improve adherence and compliance. Clinical trials have shown LaGH formulations to be effective and safe in children with GH deficiency (GHD). Somatrogon (Ngenla) is licensed for use in children with GHD over than 3 years of age.Objective: We report the real-world experience of using once wee...

ea0085p45 | Pituitary and Growth 1 | BSPED2022

The use of 6-monthly GnRH analogues in the paediatric population

Apperley Louise , Dharmaraj Poonam , Blair Joanne , Ramakrishnan Renuka , Das Urmi , Didi Mohamed , Laing Peter , Yung Zoe , Cassidy Kelly , Blundell Pauline , Jarvis Charlotte , Parkinson Jennifer , Senniappan Senthil

Background: Pubertal progression is inhibited in central precocious puberty with the use of gonadotropin releasing hormone (GnRH) analogues. They are usually given every 10 to 12 weeks via an intramuscular depot, but more recently, a 6-monthly preparation has become available for clinical use.Aim: The aim of this project was to evaluate the efficacy and acceptability of 6-monthly triptorelin, a GnRH analogue, at a tertiary childrenÂ’s hospital.<p...